NCT06636500

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of CG001419 Administered Orally to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Cullgen Australia Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.

Conditions

• Healthy Volunteer Study
• Pain Management

Interventions

Type	Name	Description
DRUG	CG001419	Oral doses
DRUG	Placebo	Oral doses

Timeline

• Start date: 2025-01-22
• Primary completion: 2025-12-05
• Completion: 2025-12-05
• First posted: 2024-10-10
• Last updated: 2026-02-20

Locations

1 site across 1 country: Australia